Neurology · 2007 · 87 citations · 5 references
MedicineOncologyPharmacotherapyChemotherapyNeuro-oncologyBrain TumorsCentral Nervous System Tumor PharmacotherapyGlioblastomaNeuro-oncology Clinical TrialsNeurotoxicity ManagementToxicity ManagementGlioblastoma ChemotherapyGlioblastoma Clinical TrialsGlioblastoma Drug TherapyGlioma ChemotherapyTemozolomide Therapy
We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.
5
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma
Wolfgang Wick, Joachim P. Steinbach, Wilhelm Küker et al. · Neurology · 2004 · 156 citations
Medicine, Oncology, Pharmacotherapy +17
The role of tumor resection in the treatment of glioblastoma multiforme in adults
Friedrich W. Kreth, Ansgar Berlis, Vicki Spiropoulou et al. · Cancer · 1999 · 118 citations · Full text